« Nancy Wexler | Main | Camp Squamish »
June 18, 2004
Minocycline
A pilot study testing HD patients tolerance to minocycline was just published. The results were as expected..."no serious adverse events were noted".
Now the drug, which has shown promise in slowing down HD in animals, can proceed to more human testing. Here's the study abstract:
Mov Disord. 2004 Jun;19(6):692-5.
Minocycline in Huntington's disease: A pilot study.
Thomas M, Ashizawa T, Jankovic J.
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6-month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini-Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted. Copyright 2004 Movement Disorder Society
PMID: 15197710
Posted by Dave at June 18, 2004 10:33 PM
Trackback Pings
TrackBack URL for this entry:
http://www.huntingtons.info/MT/mt-tb.cgi/471
Comments
Post a comment
Thanks for signing in, . Now you can comment. (sign out)
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)